Corcept, Clovis Score Wins in Advanced Ovarian Cancer

One bright spot in a week otherwise dominated by negative clinical trial news has been the field of ovarian cancer research where two biopharma companies achieved positive results in mid and late-stage trials.

Data from Corcept Therapeutics' Phase II trial on a candidate drug for ovarian cancer demonstrated a 33% reduction in risk of death compared to the current standard of care.